Lopez, Hodes, Restaino, Milman & Skikos - Ortho Evra Help - The Birth Control Patch
We are David against Goliath
We are a professionally established nationwide consumer watchdog firm dedicated to acting in plaintiff's best interests.
Potential Side Effects
Ortho McNeil has been accused of failing to adequately warn consumers about life threatening Ortho
Evra side effects, such as deep vein thrombosis and pulmonary embolism.
Ortho Evra defects have received widespread consumer concern since the publication of a study indicating birth control patch users are three times more likely to suffer fatal vascular side effects than women taking oral contraceptives.
An informative website about the potential dangers caused by the Ortho Evra birth cotnrol patch.
When the FDA approved Ortho Evra patch in 2001, Ortho McNeil’s device was well received. The patch offered advantages over other birth control methods by eliminating the need to remember to take a pill every day while still allowing women more control than currently available with hormonal injections or implants. However, information prior to approval of the Ortho Evra patch indicates that both the FDA and Ortho McNeil saw warnings signs of possible problems before the patch reached the market.
Learn More > | Ortho Evra Defects | Ortho Evra Failure
Ortho Evra Side Effects | Ortho Evra Patch | Ortho Evra Symptoms
Ortho McNeil's Ortho Evra birth control patch was FDA approved in the United States in 2001. At the time of the approval, the agency did not require any follow-up studies beyond routine FDA reviews of reports called in by consumers, doctors, and manufacturers-despite an FDA reviewer recommending the device's label clearly reflect his safety concerns about a potential for increased risk of blood clots.
Patients who experience any unusual or unexplained Ortho Evra symptoms may wish to speak with their physician in greater detail to ensure that these symptoms do not indicate a more serious health condition. Ortho Evra is a birth control patch that was approved by the FDA in 2001.
